Humira biosimilars and the rebate wall
“Humira biosimilars are essential for patients and the healthcare system since they can lower out-of-pocket costs. However, several challenges impede market penetration. Again, we have the wacky flow of money in the drug supply chain where PBMs (in charge of insurers’ formularies) favor high-priced drugs since they get a percentage of that price in rebates. In the EU, they’re not dealing with rebates, so Humira biosimilar market penetration occurred relatively quickly (they favor low-priced drugs).”
Originally posted on LinkedIn, where the discussion and source links live in the comments.